• 1
    Bergquist, C., Johansson, E. L., Lagergard, T., Holmgren, J. and Rudin, A., Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 1997. 65: 26762684
  • 2
    Wu, H. Y., Abdu, S., Stinson, D. and Russell, M. W., Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect. Immun. 2000. 68: 55395545
  • 3
    Kuper, C. F., Koornstra, P. J., Hameleers, D. M. H., Biewenga, J., Spit, B. J., Duijvestijn, A. M., van Breda Vriesman, P. J. C. et al., The role of nasopharyngeal lymphoid tissue. Immunol. Today 1992. 13: 219224
  • 4
    Liang, B., Hyland, L. and Hou, S., Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J. Virol. 2001. 75: 54165420.
  • 5
    Singleton, R., Etchart, N., Hou, S. and Hyland, L., Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J. Virol. 2003. 77: 1130311311.
  • 6
    Hall, C. B., Walsh, E. E., Long, C. E. and Schnabel, K. C., Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 1991. 163: 693698.
  • 7
    Henderson, F. W., Collier, A. M., Clyde, W. A., Jr. and Denny, F. W., Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 1979. 300: 530534.
  • 8
    Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F. and Griffin, M. R., Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. 2000. 137: 865870.
  • 9
    Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stout, J. W. and Anderson, L. J., Bronchiolitis-associated hospitalizations among US children, 1980–1996. Jama 1999. 282: 14401446.
  • 10
    Jaovisidha, P., Peeples, M. E., Brees, A. A., Carpenter, L. R. and Moy, J. N., Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J. Immunol. 1999. 163: 28162820.
  • 11
    Johnson, J. E. and Graham, B. S., The histopathology of fatal untreated human RSV infection: An archival study of autopsy material. In Anderson, L. J., Graham, B., Groothuis, J., Prince, G. A. (Eds) RSV after 43 years. Hutchinson Island, Stuart, FL 1999, pp 19251959.
  • 12
    Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. and Stewart, C. E., An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 1969. 89: 405421.
  • 13
    Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. and Parrott, R. H., Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969. 89: 422434.
  • 14
    Connors, M., Kulkarni, A. B., Firestone, C. Y., Holmes, K. L., Morse, H. C., 3rd, Sotnikov, A. V. and Murphy, B. R., Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 1992. 66: 74447451.
  • 15
    Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. and Anderson, L. J., Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 1996. 70: 28522860.
  • 16
    Alwan, W. H., Kozlowska, W. J. and Openshaw, P. J., Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 1994. 179: 8189.
  • 17
    Schwarze, J., Cieslewicz, G., Joetham, A., Ikemura, T., Hamelmann, E. and Gelfand, E. W., CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J. Immunol. 1999. 162: 42074211.
  • 18
    Dixon, G. L., Newton, P. J., Chain, B. M., Katz, D., Andersen, S. R., Wong, S., van der Ley, P. et al., Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: Interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. Infect. Immun. 2001. 69: 43514357.
  • 19
    Hilkens, C. M., Kalinski, P., de Boer, M. and Kapsenberg, M. L., Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997. 90: 19201926.
  • 20
    Massari, P., Henneke, P., Ho, Y., Latz, E., Golenbock, D. T. and Wetzler, L. M., Cutting edge: Immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 2002. 168: 15331537.
  • 21
    Fan, J., Kapus, A., Marsden, P. A., Li, Y. H., Oreopoulos, G., Marshall, J. C., Frantz, S. et al., Regulation of Toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J. Immunol. 2002. 168: 52525259.
  • 22
    Defrance, T., Vanbervliet, B., Briere, F., Durand, I., Rousset, F. and Banchereau, J., Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 1992. 175: 671682.
  • 23
    Trinchieri, G., The two faces of interleukin 12: A pro-inflammatory cytokine and a key immunoregulatory molecule produced by antigen-presenting cells. Ciba Found. Symp. 1995. 195: 203214.
  • 24
    Walsh, E. E., Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 1993. 11: 11351138.
  • 25
    Walsh, E. E., Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J. Infect. Dis. 1994. 170: 345350.
  • 26
    Bastien, N., Trudel, M. and Simard, C., Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 1999. 17: 832836.
  • 27
    Hu, K. F., Elvander, M., Merza, M., Akerblom, L., Brandenburg, A. and Morein, B., The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol. 1998. 113: 235243.
  • 28
    Hu, K. F., Lovgren-Bengtsson, K. and Morein, B., Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 2001. 51: 149159.
  • 29
    Hsu, S. C., Chargelegue, D. and Steward, M. W., Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. Virology 1998. 240: 376381.
  • 30
    Simmons, C. P., Hussell, T., Sparer, T., Walzl, G., Openshaw, P., and Dougan, G., Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J. Immunol. 2001. 166:11061113
  • 31
    Fredriksen, J. H., Rosenqvist, E., Wedege, E., Bryn, K., Bjune, G., Frøholm, L. O. et al., Production, characterization and control of MenB-vaccine “Folkehelsa”: An outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991. 14: 6779
  • 32
    Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, Ø., Fredriksen, J. H., Halstensen, A., Holten, E. et al., Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991. 338: 10931096.
  • 33
    Martin, S., Sadler, F., Borrow, R., Dawson, M., Fox, A. and Cartwright, K., IgG antibody subclass responses determined by immunoblot in infants’ sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine. Vaccine 2001. 19: 44044408.
  • 34
    Haneberg, B., Dalseg, R., Wedege, E., Hoiby, E. A., Haugen, I. L., Oftung, F., Andersen, S. R. et al., Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 1998. 66: 13341341.
  • 35
    Katial, R. K., Brandt, B. L., Moran, E. E., Marks, S., Agnello, V. and Zollinger, W. D., Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 2002. 70: 702707.
  • 36
    Budowsky, E. I., Friedman, E. A., Zheleznova, N. V. and Noskov, F. S., Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 1991. 9: 398402.
  • 37
    Mbiguino, A. and Menezes, J., Purification of human respiratory syncytial virus: Superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J. Virol. Methods 1991. 31: 161170.
  • 38
    Andersen, S. R., Bjune, G., Lyngby, J., Bryn, K. and Jantzen, E., Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb. Pathog. 1995. 19: 159168.
  • 39
    Asanuma, H., Thompson, A. H., Iwasaki, T., Sato, Y., Inaba, Y., Aizawa, C., Kurata, T. et al., Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods 1997. 202: 123131.
  • 40
    Logan, A. C., Chow, K. P., George, A., Weinstein, P. D. and Cebra, J. J., Use of Peyer's patch and lymph node fragment cultures to compare local immune responses to Morganella morganii. Infect. Immun. 1991. 59: 10241031.